Archive ready

2026年3月期 第1四半期決算短信〔日本基準〕(連結)

https://www.cawachi.co.jp/wp/wp-content/uploads/ir-tan20250724.pdf
May 13, 2026 at 12:35 AM JSTThe archive page, viewer, and downloads use this saved version.
May 13, 2026 at 12:35 AM JST·www.cawachi.co.jp

The evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.

Saved PDF

2026年3月期 第1四半期決算短信〔日本基準〕(連結)

StartedMay 13, 2026 at 12:35 AM JST
File size0.23 MB
SHA-256b1616ada512ba7f5765e7fca8dd22a664455ede663e35314a96456699aa1e8e1
About this pageAI generated

This document is the consolidated financial results report for the first quarter of the fiscal year ending March 2026, published by Kawachi Pharmaceutical Co., Ltd. on July 24, 2025. It covers the period from March 16, 2025, to June 15, 2025. The report indicates that sales amounted to 71.025 billion yen, a 0.4% decrease compared to the same period last year. Operating profit decreased by 22.2% to 1.249 billion yen, and ordinary profit decreased by 11.5% to 1.611 billion yen. The net profit attributable to the parent company was 1.045 billion yen, also down by 11.5%. Despite a gradual economic recovery, challenges such as rising prices and intensified competition are noted, prompting the company to enhance its health food offerings and review pricing strategies.